复方菝葜颗粒联合吉非替尼治疗中晚期非小细胞肺癌30例  

Clinical effect of compound Baqia granules combined with gefitinib in treatment of advanced non-small cell lung cancer:An analysis of 30 cases

作　　者：倪道雯 王容容 柏正平(指导)[3] NI Daowen;WANG Rongrong;BAI Zhengping(Hunan University of Chinese Medicine,Changsha 410208,Hunan,China;The Affiliated Hospital of Hunan Academy of Chinese Medicine,Changsha 410006,Hunan,China;Hunan Academy of Chinese Medicine,Changsha 410006,Hunan,China)

机构地区：[1]湖南中医药大学,湖南长沙410208 [2]湖南省中医药研究院附属医院,湖南长沙410006 [3]湖南省中医药研究院,湖南长沙410006

出　　处：《湖南中医杂志》2022年第11期6-9,共4页Hunan Journal of Traditional Chinese Medicine

摘　　要：目的:观察复方菝葜颗粒联合吉非替尼治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将60例中晚期NSCLC患者随机分为治疗组与对照组,每组各30例。对照组予以吉非替尼治疗,治疗组在此基础上加用复方菝葜颗粒治疗。治疗2个周期后比较2组实体瘤疗效、中医证候疗效、Karnofsky行为状态评分(KPS)、肿瘤标志物血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平及不良反应发生情况。结果:客观缓解率、疾病控制率治疗组分别为20.00%(6/30)、86.67%(26/30),对照组分别为10.00%(3/30)、76.67%(23/30),2组比较,差异无统计学意义(P>0.05);中医证候疗效治疗组为83.33%(25/30),对照组为53.33%(16/30),2组比较,差异有统计学意义(P<0.05);2组KPS评分较治疗前均有所升高,CEA、CYFRA21-1水平均有所下降,且治疗组升高、下降幅度均大于对照组(P<0.05);治疗组的腹泻与皮疹发生率分别为23.33%(7/30)、36.67%(11/30),均低于对照组的46.67%(14/30)、53.33%(16/30),2组比较,差异有统计学意义(P<0.05)。结论:复方菝葜颗粒联合吉非替尼治疗中晚期NSCLC在缓解症状,减少不良反应的发生,降低CEA、CYFRA21-1水平与提高KPS评分方面疗效较好,具有临床推广价值。Objective:To investigate the clinical effect of compound Baqia granules combined with gefitinib in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 60 patients with advanced NSCLC were randomly divided into treatment group and control group,with 30 patients in each group.The patients in the control group were given gefitinib,and those in the treatment group were given compound Baqia granules in addition to the treatment in the control group.After two courses of treatment,the two groups were compared in terms of response of solid tumor,response of traditional Chinese medicine(TCM)syndrome,Karnofsky Performance Scale(KPS)score,serum levels of the tumor markers carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1),and adverse reactions.Results:There were no significant differences between the treatment group and the control group in objective response rate[20.00%(6/30)vs 10.00%(3/30),P>0.05]and disease control rate[86.67%(26/30)vs 76.67%(23/30),P>0.05],and there was a significant difference in the response of TCM syndrome between the two groups[83.33%(25/30)vs 53.33%(16/30),P<0.05].After treatment,both groups had a significant increase in KPS score and significant reductions in the levels of CEA and CYFRA21-1,and the treatment group had significantly greater changes than the control group(P<0.05).Compared with the control group,the treatment group had significantly lower incidence rates of diarrhea[23.33%(7/30)vs 46.67%(14/30),P<0.05]and rash[36.67%(11/30)vs 53.33%(16/30),P<0.05].Conclusion:In the treatment of advanced NSCLC,compound Baqia granules combined with gefitinib have a marked clinical effect in alleviating symptoms,reducing adverse reactions and the levels of CEA and CYFRA21-1,and improving KPS score,and thus it holds promise for clinical application.

关 键 词：非小细胞肺癌 复方菝葜颗粒 吉非替尼 临床疗效 

分 类 号：R273.42[医药卫生—中西医结合]